RXRX News & Analysis
2 articles
Market Mood
Recursion Pharmaceuticals (RXRX) Files Form 144 on July 6
Recursion Pharmaceuticals (RXRX) submitted a Form 144 on July 6, signaling intent to sell shares. This form typically indicates a potential sale of restricted securities by insiders. The disclosure can suggest to investors that insiders may anticipate changes in stock performance. Such actions can impact market perceptions of the company's future prospects and share price volatility.
Read More: Recursion Pharmaceuticals (RXRX) Files Form 144 on July 6
Moderna (MRNA) Revenue Declines 40% in FY 2025, Losses Continue
In FY 2025, Moderna (MRNA) reported revenue exceeding $1.9 billion, a 40% decrease from the prior year, alongside a net loss of approximately $2.8 billion. The company's debt-to-equity ratio was about 0.2x, and free cash flow was nearly $2.1 billion negative. In comparison, Recursion Pharmaceuticals (RXRX) generated approximately $74.7 million in revenue, marking a 27% year-over-year increase, but recorded a net loss of nearly $645 million. Its debt-to-equity ratio stood at around 0.1x, with free cash flow of about negative $378 million, indicating significant investment in its infrastructure.
Read More: Moderna (MRNA) Revenue Declines 40% in FY 2025, Losses Continue